Fifteen years of rifampicin-resistant TB control in Niger: high countrywide treatment uptake and success
IJTLD Open · 2026-01 · 3 (1) · 4-10
DOI: 10.5588/ijtldopen.25.0455 ↗Kurz gefasst
Fachartikel in der Zeitschrift IJTLD Open, online erschienen am 01.01.2026. Verfasst von I Maman Lawan und 17 weiteren Autor:innen. Beteiligte Einrichtung: Damien Foundation, Niamey, Niger. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND Few rifampicin-resistant TB (RR-TB) studies show pre-treatment outcomes and definitive treatment outcomes (accounting for RR-TB re-treatment). Our Niger countrywide study covered 15 years to show the trend of RR-TB diagnoses, time-to-treatment initiation, and pre-and on-treatment attrition (loss to follow-up or death). METHODS Retrospective study including all Niger RR-TB patients diagnosed between 2008 and 2022. RESULTS 872 RR-TB patients were diagnosed, 725 (83.1%) started treatment, and 32 required retreatment. Between 2008 and 2013 (phenotypic testing), 2014 and 2018 (regional molecular testing), and 2019 and 2022 (decentralised molecular testing), the annual average first RR-TB treatment initiations increased from 22 to 50 and 85, and the median time to first RR-TB treatment reduced from 260 to 17 and 11 days, by period. Pre-treatment attrition reduced from 34.1% to 12.8% and 12.6%. On-treatment attrition increased from 8.8% to 13.5% and 19.8%. Overall, 81.7% ( N = 725) experienced definitive treatment success. On-treatment attrition was 18.3%, predicted by older age, female gender, low BMI, RR-TB/HIV co-infection, high baseline bacillary load, and treatment initiation between 2019 and 2022. CONCLUSION In Niger, over 15 years of RR-TB control, pre-treatment attrition reduced over time, reflecting better access to care. Treatment success was high, exceeding global success. However, increasing on-treatment attrition should be addressed by targeting high-risk groups.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Damien Foundation, Niamey, Niger.
- Institute of Tropical Medicine, TB-HIV Unit, Antwerp, Belgium.
- Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.
- National Tuberculosis Programme, Coordination, Niamey, Niger.
- Hôpital National Amirou Boubarcar Djallo, Sercive Pneumo-Phtysiologie, Niamey, Niger.
- Faculté des Science de la Santé, Université Abdou Moumouni de Niamey, Niamey, Niger.
Zitieren
APA
Maman Lawan, I., Decroo, T., Souleymane, M. B., Soumana, A., Aboubacar, C. L., Gagara, A., Hamissou Moussa, R., Kabirou Amoussa, A. A., Hamidou, I., Hamidou Moussa, S., Adamou, M., Adehossi, E., Mamadou, S., Catherine de Jong, B., Rigouts, L., Lorent, N., Doutchi, M., & Piubello, A. (2026). Fifteen years of rifampicin-resistant TB control in Niger: high countrywide treatment uptake and success. IJTLD Open, 3(1), 4-10. https://doi.org/10.5588/ijtldopen.25.0455
Vancouver
Maman Lawan I, Decroo T, Souleymane MB, Soumana A, Aboubacar CL, Gagara A, et al. Fifteen years of rifampicin-resistant TB control in Niger: high countrywide treatment uptake and success. IJTLD Open. 2026;3(1):4-10. doi:10.5588/ijtldopen.25.0455
BibTeX
@article{MamanLawan2026,
author = {Maman Lawan, I and Decroo, T and Souleymane, M B and Soumana, A and Aboubacar, C L and Gagara, A and Hamissou Moussa, R and Kabirou Amoussa, A A and Hamidou, I and Hamidou Moussa, S and Adamou, M and Adehossi, E and Mamadou, S and Catherine de Jong, B and Rigouts, L and Lorent, N and Doutchi, M and Piubello, A},
title = {Fifteen years of rifampicin-resistant TB control in Niger: high countrywide treatment uptake and success},
journal = {IJTLD Open},
year = {2026},
volume = {3},
number = {1},
pages = {4--10},
doi = {10.5588/ijtldopen.25.0455}
}
EUVIMED